Detrusor Underactivity and Bladder Outlet Procedures in Men
- 21 Downloads
Purpose of Review
Detrusor underactivity (DU) is a common but poorly understood clinical problem. The diagnosis and treatment of DU are difficult and full of uncertainties. There are many overlaps between DU and bladder outlet obstruction (BOO) in clinical symptoms and managements. In this review, we discuss the relationship of clinical diagnosis and treatment between DU and BOO in men, especially the outcome of bladder outlet surgery in patients with DU.
DU could be resulted from many different etiologies, including psychogenic, neurogenic, myogenic, and the reduced detrusor contractility after increasing muscle work against the increase of bladder outlet resistance. Current managements are usually focused on relieving voiding difficulty and prevent urine retention to avoid urinary tract infection and upper urinary tract deterioration. Since there is no suitable medical treatment to enhance bladder contractility, most of the researches focus on reducing bladder outlet resistance and treat BOO. Many recent studies have reported the therapeutic outcome of transurethral incision of the bladder neck, transurethral resection of the prostate and urethral sphincter botulinum toxin A injection.
The current treatment options in DU are limited. Even if there are many clinical trials revealing good results in patients with DU after BOO surgery, the evidence that BOO surgeries benefit patients with DU are still controversial. The actual mechanism of detrusor function recovery after BOO surgery in men with DU has not been well elucidated. Nevertheless, a portion of men with DU can safely and effectively improve their voiding symptoms and voiding efficiency after BOO surgeries. Further research of the underlying pathophysiology between DU and BOO is mandatory.
KeywordsBenign prostatic hyperplasia Bladder outlet obstruction Detrusor underactivity Lower urinary tract symptoms
Compliance with Ethical Standards
Conflict of Interest
Shu-Yu Wu declares that he has no conflict of interest.
Yuan-Hong Jiang declares that he has no conflict of interest.
Hann-Chorng Kuo declares that he has no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 1.Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al. Standardisation sub-committee of the international continence society. The standardisation of terminology of lower urinary tract function: report from the standardisation sub-committee of the international continence society. Neurourol Urodyn. 2002;21:167–78.CrossRefGoogle Scholar
- 2.•• Chapple CR, Osman NI, Birder L, van Koeveringe GA, Oelke M, Nitti VW, et al. The underactive bladder: a new clinical concept? Eur Urol. 2015;68:351–3. A comprehensive review of bladder underactivity, with international expert group presents a working definition for the symptoms that characterise bladder underactivity, with the aim of facilitating further research in this area. CrossRefGoogle Scholar
- 7.• Juszczak K, Drewa T. Pharmacotherapy in detrusor underactivity: a new challenge for urologists and pharmacologists (from lab to clinic). Pharmacol Rep. 2016;68:703–6. A review of the potential pharmacological targets in DU treatment in the animal model. The potential pharmacological targets in DU therapy were discussed, such as bombesin receptors, prostaglandin-, ATP-, NO-, CGRP-, SP-, Dopamine-, NGF-, M2-, and agrin-dependent pathways. CrossRefGoogle Scholar
- 14.•• Smith PP, Chalmers DJ, Feinn RS. Does defective volume sensation contribute to detrusor underactivity? Neurourol Urodyn. 2015;34:752–6. The urodynamic finding of detrusor underactivity (DU) in neurologically intact unobstructed patients revealed that diminished central sensitivity to volume afferent activity contributes to DU. CrossRefGoogle Scholar
- 15.•• Jiang YH, Kuo HC. Urothelial barrier deficits, suburothelial inflammation and altered sensory protein expression in detrusor underactivity. J Urol. 2017;197:197–203. A comprehensive human study of urothelial dysfunction in patients with DU, revealed that urothelial dysfunction, increased suburothelial inflammation and altered sensory protein expressions in bladder mucosa were prominent in patients with DU. Impaired urothelial signaling and sensory transduction pathways appear to reflect the pathophysiology of DU. CrossRefGoogle Scholar
- 16.• Yang TH, Chuang FC, Kuo HC. Urodynamic characteristics of detrusor underactivity in women with voiding dysfunction. PLoS One. 2018;13:e0198764. A large cohort of women with voiding dysfunction revealed that bladder contractility index and voiding efficiency were significantly lowest in DU patients than normal tracing group. Reduced bladder sensation was noted in DU and negatively associated with detrusor contractility. CrossRefGoogle Scholar
- 20.• Jiang YH, Liao CH, Kuo HC. Role of bladder dysfunction in men with lower urinary tract symptoms refractory to alpha-blocker therapy: a video-urodynamic analysis. Low Urin Tract Symptoms. 2018;10:32–7. A clinical study of 2991 men with LUTS revealed that one-third of male LUTS was due to bladder dysfunction. A man older than 70 years with LUTS and total prostate volume less than 30 mL usually indicates the presence of bladder dysfunction rather than BOO. CrossRefGoogle Scholar
- 22.•• Jiang YH, Kuo HC. Video-urodynamic characteristics of non-neurogenic, idiopathic underactive bladder in men – a comparison of men with normal tracing and bladder outlet obstruction. PLoS One. 2017;12:e0174593. This study analyzed the video-urodynamic study characteristics of patients with underactive bladder in a large cohort of men with lower urinary tract symptoms (LUTS). VUDS findings in DU patients showed a slowly increased detrusor pressure, intermittent detrusor contractions, or early decline of detrusor contraction, resulting in a low maximum flow rate , and large PVR. CrossRefGoogle Scholar
- 25.•• Rademakers KL, van Koeveringe GA, Oelke M. Detrusor underactivity in men with lower urinary tract symptoms/benign prostatic obstruction: characterization and potential impact on indications for surgical treatment of the prostate. Curr Opin Urol. 2016;26:3–10. A comprehensive review of DU in men with LUTS. The authors point out careful assessment of voiding dysfunction to differential diagnosis between DU and BOO is important, and should be done with pressure flow study. CrossRefGoogle Scholar
- 29.•• Jiang YH, Wang CC, Kuo HC. Videourodynamic findings of lower urinary tract dysfunctions in men with persistent storage lower urinary tract symptoms after medical treatment. PLoS One. 2018;13:e0190704. This study analyzed the underlying lower urinary tract dysfunctions by video-urodynamic studies in men who have persistent storage symptoms after initial drug therapy for LUTS suggestive of BPH. In men who have persistent storage symptoms after medical treatment for LUTS/BPH, BOO should be carefully investigated and appropriate management being given to improve LUTS. CrossRefGoogle Scholar
- 30.Thomas AW, Cannon A, Bartlett E, Ellis-Jones J, Abrams P. The natural history of lower urinary tract dysfunction in men: the influence of detrusor underactivity on the outcome after transurethral resection of the prostate with a minimum 10-year urodynamic follow-up. BJU Int. 2004;93:745–50.CrossRefGoogle Scholar
- 34.Masumori N, Furuya R, Tanaka Y, Furuya S, Ogura H, Tsukamoto T. The 12-year symptomatic outcome of transurethral resection of the prostate for patients with lower urinary tract symptoms suggestive of benign prostatic obstruction compared to the urodynamic findings before surgery. BJU Int. 2010;105:1429–33.CrossRefGoogle Scholar
- 39.• Woo MJ, Ha YS, Lee JN, Kim BS, Kim HT, Kim TH, et al. Comparison of surgical outcomes between holmium laser enucleation and transurethral resection of the prostate in patients with detrusor underactivity. Int Neurourol J. 2017;21:46–52. The study reports that HoLEP can be effectively and safely performed in patients with BPH and clinically DU. The therapeutic outcome was better than TURP in DU patients. CrossRefGoogle Scholar
- 40.Cho MC, Ha SB, Park J, Son H, Oh SJ, Kim SW, et al. Impact of detrusor underactivity on surgical outcomes of laser prostatectomy: comparison in serial 12-month follow-up outcomes between potassium-titanyl-phosphate photoselective vaporization of the prostate (PVP) and holmium laser enucleation of the prostate (HoLEP). Urology. 2016;91:158–66.CrossRefGoogle Scholar
- 41.• Cho MC, Park J, Kim JK, Cho SY, Jeong H, Oh SJ, et al. Can preoperative detrusor underactivity influence surgical outcomes of 120 W HPS vaporization of the prostate (PVP) or holmium laser enucleation of the prostate (HoLEP)? A serial 3-year follow-up study. Neurourol Urodyn. 2018;37:407–16. Improvements in LUTS, Qmax, and bladder voiding efficiency (BE) can maintain up to 3 years after HPS vaporization of the prostate (PVP) or holmium laser enucleation of the prostate (HoLEP) for LUTS/BPH, irrespective of the presence or absence of preoperative DU. However, there was no difference in improvement of QOL or Qmax or BVE between PVP and HoLEP. CrossRefGoogle Scholar
- 42.• Jiang YH, Jhang JF, Chen SF, Kuo HC. Videourodynamic factors predictive of successful onabotulinumtoxinA urethral sphincter injection for neurogenic or non-neurogenic detrusor underactivity. Low Urin Tract Symptoms. 2017. https://doi.org/10.1111/luts.12195. This clinical trial revealed that urethral sphincter injection of onabotulinumtoxinA is effective in 60% of patients with DU. Careful videourodynamic interpretation of bladder neck opening enables urologists to select appropriate candidates for onabotulinumtoxinA treatment.
- 45.•• Jiang YH, Lee CL, Jhang JF, Kuo HC. Current pharmacological and surgical treatment of underactive bladder. Ci Ji Yi Xue Za Zhi. 2017;29:187–91. This is a comprehensive review of current treatment strategy. Treatment of UAB or DU aims to reduce the postvoid residual urine volume and increase voiding efficiency, either by spontaneous voiding or abdominal straining. Pharmacotherapy with parasympathomimetics or cholinesterase inhibitors might be tried, and benefits can be achieved in combination with alpha-blockers. Bladder outlet surgeries, including urethral onabotulinumtoxinA injection, transurethral incision of the bladder neck, and transurethral incision or resection of the prostate can effectively improve voiding efficiency and decrease the PVR in most patients with DU. PubMedPubMedCentralGoogle Scholar
- 49.•• Jiang YH, Wang CC, Kuo HC. OnabotulinumtoxinA urethral sphincter injection as treatment for non-neurogenic voiding dysfunction – a randomized, double-blind, placebo-controlled study. Sci Rep. 2016;6:38905. This randomized, double-blind, placebo-controlled trial was designed to determine the clinical efficacy of onabotulinumtoxinA urethral sphincter injections in patients with dysfunctional voiding or detrusor underactivity. For patients with non-neurogenic voiding dysfunction, the success rate of onabotulinumtoxinA urethral sphincter injection was not superior to placebo. Repeat urethral sphincter onabotulinumtoxinA injections offered greater therapeutic effects in both dysfunctional voiding and detrusor underactivity patients. CrossRefGoogle Scholar
- 52.•• Jiang YH, Chen SF, Jhang JF, Kuo HC. Therapeutic effect of urethral sphincter onabotulinumtoxinA injection for urethral sphincter hyperactivity. Neurourol Urodyn. 2018. https://doi.org/10.1002/nau.23714. This clinical trial revealed that subjective improvement was reported in 61.1% of patients with voiding dysfunction due to urethral sphincter hyperactivity after onabotulinumtoxinA urethral sphincter injection. An open bladder neck during voiding at baseline predicts a successful outcome.